Article: GREENER Pharmaceuticals for More Sustainable Healthcare

Medicines are essential to human health but can also impact the aquatic and terrestrial environment after use by patients and release via excreta into wastewater. We highlight the need for a GREENER approach to identify and meet important environmental criteria, which will help reduce the impact of medicinal residues on the environment. These criteria include effect reduction by avoiding nontarget effects or undesirable moieties, exposure reduction via lower emissions or environmental (bio)degradability, no PBT (persistent, bioaccumulative, and toxic) substances, and risk mitigation. With all of these criteria, however, patient health is of primary importance as medicines are required to be safe and efficacious for treating diseases. We discuss the feasibility of including these criteria for green by design active pharmaceutical ingredients in the process of drug discovery and development and which tools or assays are needed to accomplish this. The integrated GREENER approach can be used to accelerate discussions about future innovations in drug discovery and development.

Citing Articles

Read-Across of Biotransformation Potential between Activated Sludge and the Terrestrial Environment: Toward Making It Practical and Plausible.

Coll C, Screpanti C, Hafner J, Zhang K, Fenner K Environ Sci Technol. 2025; 59(3):1790-1800.

PMID: 39809460 PMC: 11780744. DOI: 10.1021/acs.est.4c09306.

A review on emerging pharmaceutical residues in Ethiopia: occurrence, ecotoxicological aspects, and regulatory concerns.

Tegegne A, Mekasha Y, Ayu A, Hasen G, Suleman S Front Microbiol. 2025; 15:1499487.

PMID: 39760084 PMC: 11695420. DOI: 10.3389/fmicb.2024.1499487.

Tackling Pharmaceutical Pollution Along the Product Lifecycle: Roles and Responsibilities for Producers, Regulators and Prescribers.

Parker G, Miller F Pharmacy (Basel). 2024; 12(6).

PMID: 39585099 PMC: 11587451. DOI: 10.3390/pharmacy12060173.

Environmental impacts of drugs against parasitic vector-borne diseases and the need to integrate sustainability into their development and use.

Lima C, Uliassi E, Thore E, Bertram M, Cardoso L, Cordeiro da Silva A Open Res Eur. 2024; 4:207.

PMID: 39534878 PMC: 11555358. DOI: 10.12688/openreseurope.18008.2.

Nanoformulations in Pharmaceutical and Biomedical Applications: Green Perspectives.

Petrovic S, Bita B, Barbinta-Patrascu M Int J Mol Sci. 2024; 25(11).

PMID: 38892030 PMC: 11172476. DOI: 10.3390/ijms25115842.

References

1.

Wilkinson J, Boxall A, Kolpin D, Leung K, Lai R, Galban-Malagon C . Pharmaceutical pollution of the world's rivers. Proc Natl Acad Sci U S A. 2022; 119(8). PMC: 8872717. DOI: 10.1073/pnas.2113947119. View

2.

Miller T, Bury N, Owen S, MacRae J, Barron L . A review of the pharmaceutical exposome in aquatic fauna. Environ Pollut. 2018; 239:129-146. PMC: 5981000. DOI: 10.1016/j.envpol.2018.04.012. View

3.

Miller E, Nason S, Karthikeyan K, Pedersen J . Root Uptake of Pharmaceuticals and Personal Care Product Ingredients. Environ Sci Technol. 2015; 50(2):525-41. DOI: 10.1021/acs.est.5b01546. View

4.

Kamrin M . The "low dose" hypothesis: validity and implications for human risk. Int J Toxicol. 2007; 26(1):13-23. DOI: 10.1080/10915810601117968. View

5.

Kidd K, Blanchfield P, Mills K, Palace V, Evans R, Lazorchak J . Collapse of a fish population after exposure to a synthetic estrogen. Proc Natl Acad Sci U S A. 2007; 104(21):8897-901. PMC: 1874224. DOI: 10.1073/pnas.0609568104. View

6.

Verbruggen B, Gunnarsson L, Kristiansson E, Osterlund T, Owen S, Snape J . ECOdrug: a database connecting drugs and conservation of their targets across species. Nucleic Acids Res. 2017; 46(D1):D930-D936. PMC: 5753218. DOI: 10.1093/nar/gkx1024. View

7.

Domingo-Echaburu S, Davalos L, Orive G, Lertxundi U . Drug pollution & Sustainable Development Goals. Sci Total Environ. 2021; 800:149412. DOI: 10.1016/j.scitotenv.2021.149412. View

8.

der Beek T, Weber F, Bergmann A, Hickmann S, Ebert I, Hein A . Pharmaceuticals in the environment--Global occurrences and perspectives. Environ Toxicol Chem. 2015; 35(4):823-35. DOI: 10.1002/etc.3339. View

9.

Moermond C, de Rooy M . The Dutch chain approach on pharmaceuticals in water: Stakeholders acting together to reduce the environmental impact of pharmaceuticals. Br J Clin Pharmacol. 2022; 88(12):5074-5082. PMC: 9826305. DOI: 10.1111/bcp.15509. View

10.

Kar S, Sanderson H, Roy K, Benfenati E, Leszczynski J . Green Chemistry in the Synthesis of Pharmaceuticals. Chem Rev. 2021; 122(3):3637-3710. DOI: 10.1021/acs.chemrev.1c00631. View

11.

Morgan P, Brown D, Lennard S, Anderton M, Barrett J, Eriksson U . Impact of a five-dimensional framework on R&D productivity at AstraZeneca. Nat Rev Drug Discov. 2018; 17(3):167-181. DOI: 10.1038/nrd.2017.244. View

12.

Kahn L . Perspective: The one-health way. Nature. 2017; 543(7647):S47. PMC: 7094977. DOI: 10.1038/543S47a. View